Search

Your search keyword '"Eriksen, Erik Fink"' showing total 104 results

Search Constraints

Start Over You searched for: Author "Eriksen, Erik Fink" Remove constraint Author: "Eriksen, Erik Fink" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
104 results on '"Eriksen, Erik Fink"'

Search Results

2. Intermittent dosing of zoledronic acid based on bone turnover marker assessment reduces vertebral and non-vertebral fractures.

7. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

11. Disease-Modifying Adjunctive Therapy of Osteopenia and Osteoporosis with a Multimineral Marine Extract, LithoLexal ® Bone.

12. Bone Turnover in Relation to Thyroid-Stimulating Hormone in Hypothyroid Patients on Thyroid Hormone Substitution Therapy.

16. Thyroid Signaling Biomarkers in Female Symptomatic Hypothyroid Patients on Liothyronine versus Levothyroxine Monotherapy: A Randomized Crossover Trial.

18. Zoledronic acid and clinical fractures and mortality after hip fracture

19. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

22. Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy: A Randomized Crossover Study.

23. Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis--The Biological Effects of a Multi-Mineral Complex, LithoLexal® Joint--A Review.

25. Effect of Liothyronine Treatment on Dermal Temperature and Activation of Brown Adipose Tissue in Female Hypothyroid Patients: A Randomized Crossover Study.

31. Changes in Bone Marrow Adipose Tissue One Year After Roux‐en‐Y Gastric Bypass: A Prospective Cohort Study.

32. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report.

33. Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy.

34. High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.

35. Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study.

37. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.

38. Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.

40. Characteristics of Glucose Metabolism in Nordic and South Asian Subjects with Type 2 Diabetes.

41. Bone Turnover and Metabolism in Patients with Early Multiple Sclerosis and Prevalent Bone Mass Deficit: A Population-Based Case-Control Study.

42. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

43. Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture.

44. Perspective: Remodeling and Vascular Spaces in Bone.

Catalog

Books, media, physical & digital resources